Newsletter from Emotra AB (publ)

Göteborg, March 3, 2016

Short update – Grant Agreement signed with the European Commission

Emotra and the European Commission have now signed a Grant Agreement, which in practice amounts to a green light to initiate our strategically important Horizon 2020 Phase I study, a feasibility study for a planned larger trial testing children and youth up to 20 years of age with EDOR. On Monday, March 7 a project kick-off meeting will be arranged in Munich, Germany, and on March 12–15, Emotra will be participating at the European Psychiatric Association's international conference in Madrid, Spain. By the end of next week, EDOR testing of new patients will cease. The Company will be releasing more information in connection with this closing.

An agreement has been signed with the European Commission, EC, and we are now ready to start our Horizon 2020 Phase I study. On Monday, March 7 we will be holding a kick-off meeting in Munich with the Madrid-based company Inspiralia. This company has approximately 100 employees and is specialised in helping other companies to apply for EC grants and carrying out market-related studies. Emotra, Marco Sarchiapone and Dr. Vladimir Carli, a prominent suicide researcher at the Karolinska Institute, will be responsible for authoring the scientific, clinical and health care-related content, while Inspiralia will be responsible for carrying out the planned feasibility study and for reporting the study and its results to the European Commission. Our ambition is that Inspiralia will be compiling the application for Phase II, which is a study on children and young people up to 20 years of age.

EDOR will be in the spotlight on several different occasions during this year's most important international psychiatric conference, the EPA meeting, being held in Madrid on March 12–15. A special symposium will be led by EDOR's inventor and Emotra's Research Manager, Dr. Lars-Håkan Thorell, and Emotra's scientific advisor, Professor Marco Sarchiapone, from Molise, Italy. Furthermore, we will be holding a special workshop that focuses on the challenges in diagnosing suicide risk and what possibilities the profession sees in solving these problems. We will be presenting EDOR as a possible solution for these severe and serious problems.

The European multi-centre study on the use of EDOR for assessing suicide risk, which Emotra is conducting in close collaboration with the European Psychiatric Association's Suicide Section, EPA-SS, has proceeded at a high pace since the spring of 2015. The pace slowed down somewhat during the last weeks of December and the first weeks of January, but the high inflow of test data has been steady since then. The study's managers have decided to stop testing new patients as of the end of next week. The inflow of new test data will thereby cease the day before the Madrid conference starts. Emotra will be releasing more information in connection with this closing.

For further information, please contact: Claes Holmberg, CEO. Telephone: *+46 708 25 45 47*, *E-mail: claes@emotra.se*

Emotra AB (publ) *is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*